Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $425000.0.

  • Harvard Bioscience's Depreciation and Depletion fell 274.6% to $425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 362.02%. This contributed to the annual value of $1.7 million for FY2024, which is 1513.33% up from last year.
  • As of Q3 2025, Harvard Bioscience's Depreciation and Depletion stood at $425000.0, which was down 274.6% from $411000.0 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Depreciation and Depletion peaked at $470000.0 during Q4 2021, and registered a low of $331000.0 during Q4 2022.
  • Its 5-year average for Depreciation and Depletion is $407789.5, with a median of $418000.0 in 2023.
  • Per our database at Business Quant, Harvard Bioscience's Depreciation and Depletion plummeted by 2957.45% in 2022 and then skyrocketed by 2861.45% in 2024.
  • Harvard Bioscience's Depreciation and Depletion (Quarter) stood at $470000.0 in 2021, then dropped by 29.57% to $331000.0 in 2022, then grew by 25.98% to $417000.0 in 2023, then increased by 10.07% to $459000.0 in 2024, then decreased by 7.41% to $425000.0 in 2025.
  • Its last three reported values are $425000.0 in Q3 2025, $411000.0 for Q2 2025, and $451000.0 during Q1 2025.